What's on the label is the measured result — net peptide mass, not gross powder weight, plus RP-HPLC purity, on a lot-numbered COA for every batch.
Net peptide mass and RP-HPLC purity — a lot-numbered COA for every batch.
Net peptide mass + HPLC purity, per lot.
PCAC will review 7 peptides for the 503A bulks list, BPC-157, KPV, TB-500, MOTS-c, Emideltide, Semax, Epitalon. Read our briefing →
PCAC will review 7 peptides for the 503A bulks list. Read →
FDA PCAC reviews 7 peptides in July. Read →
Reference-name product · composition documented per batch
PeptideXpo primary owner
This PeptideXpo page is the primary SEO owner for buyers evaluating PROSTAMAX Research Preparation through broad supplier qualification, distributor assortment planning, OEM catalog coverage, and repeat-order economics. It should help the buyer decide whether this SKU belongs in a larger peptide sourcing program before specialist analytical or pharmacy documentation review.
Overview
PROSTAMAX is a reference-name product, typically marketed in the upstream supplier-catalog space as a prostate-targeting short-peptide preparation. The product is most commonly seen in Russian and Eastern European peptide-bioregulator catalogs, where reference-name preparations targeting specific organ systems are an established commercial pattern that overlaps with the Khavinson bioregulator framework. The actual composition is proprietary to the upstream manufacturer and is verified against the batch-specific COA before any order placement. PeptideXpo lists PROSTAMAX to support distributor-partner workflows that reference upstream price tables. Direct end-buyers should consider the named-molecule equivalents in the Khavinson family (when a prostate-tissue Khavinson peptide is the underlying material) or engage the regulatory team for explicit composition disclosure before ordering. The 20 mg standard vial matches the format pattern of the broader Khavinson catalog.
Who buys this, and why
Custom-blend buyers are almost always OEM clients building a branded product around a specific ratio of two or more peptides. The development workflow is collaborative: ratio target, analytical method to verify it, stability protocol in the chosen carrier, and packaging selection are all defined in the OEM brief before the first commercial run. Sample-stage volumes are usually 5-10 g of finished blend; commercial MOQ depends on the components.
Primary buyer fit: regional distributors and re-sellers.
Specifications
Documentation available on request
Regulatory note
Reference-name product without publicly disclosed API identity; composition is documented on the batch-specific COA before any downstream regulatory or research use.
Frequently asked questions
PROSTAMAX is positioned within the broader Russian-school short-peptide bioregulator framework that overlaps with the Khavinson research lineage, both share the design pattern of short tissue-specific peptide preparations marketed for the corresponding tissue indication. The exact composition of PROSTAMAX is proprietary to the upstream manufacturer and may or may not be a single defined peptide (some PROSTAMAX preparations are multi-peptide extracts similar to Cerebrolysin or Cortexin). Buyers conducting research with PROSTAMAX should request explicit composition disclosure from the regulatory team and reference the original Russian-language publications if replicating published protocols, rather than assume mechanistic equivalence to named single-peptide Khavinson products.
Russian-school publications on prostate-targeting short peptides focus on age-related benign prostatic hyperplasia (BPH) and prostate-tissue gene-expression modulation in aged-rodent models. The mechanism hypothesis within the Khavinson framework is that short tissue-specific peptides isolated from young-animal prostate tissue can act as endogenous-mimetic bioregulators of prostate gene expression, supporting tissue homeostasis and counteracting age-related dysregulation. Reported readouts in published animal studies include modulation of prostate-tissue proliferation markers and inflammation markers. As with the broader Khavinson framework, the evidence base is concentrated in Russian-language journals; PROSTAMAX should be treated as an investigational research tool rather than a clinically-validated prostate therapeutic.
Because PROSTAMAX's exact composition is proprietary to the upstream manufacturer and the molecule is not approved as a finished drug in any major regulatory framework, PeptideXpo cannot provide standard pharmaceutical-product documentation (no SPC, no monograph, no approved dosing). What we do provide on every shipment: (1) batch-specific COA covering the verified composition of the released material, (2) HPLC chromatogram and mass-spec data for the dominant species in the preparation, (3) sterility and microbial-limits testing for injectable-route applications, and (4) regulatory advisory on the destination market's current treatment of similar Russian-origin peptide preparations. Clinical use is the buyer's responsibility under their local regulatory framework.
